Inclusion Criteria:

          -  Has locally advanced or metastatic RCC with predominantly clear cell subtype

          -  Has at least one measurable lesion as defined by RECIST version 1.1

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0-1

          -  Has adequate organ function defined as follows:

               -  Absolute neutrophil count ≥ 1,000/µL, hemoglobin level ≥ 10 g/dL and platelet
                  count ≥ 100,000/µL without transfusion or growth factor support within 2 weeks
                  prior to obtaining the hematology values at screening;

               -  Serum creatinine level ≤ 2.0 × upper limit of normal (ULN)

               -  Transaminase levels (AST/ALT) ≤ 3.0 × upper limit of normal (ULN); total
                  bilirubin (TBILI) ≤ 1.5 mg/dL in the absence of Gilbert's disease *Cohort 1:
                  Participants must not have received prior systemic therapy for advanced or
                  metastatic ccRCC

          -  Cohort 2: Participants must have received prior immunotherapy and no more than two
             prior treatments for advanced or metastatic ccRCC

        Exclusion Criteria:

          -  Has received prior treatment with belzutifan or other HIF2α inhibitors

          -  Has received prior treatment with cabozantinib

          -  Has had radiation therapy for bone metastases within two weeks of starting study drug

          -  Has a history of untreated brain metastases or history of leptomeningeal disease or
             spinal cord compression

          -  Has failed to recover from the reversible effects of prior anticancer therapy

          -  Has uncontrolled or poorly controlled hypertension

          -  Is receiving anticoagulant therapy

          -  Has had any major cardiovascular event within 6 months prior to study drug
             administration

          -  Has any other clinically significant cardiac, respiratory, or other medical or
             psychiatric condition that might interfere with participation in the trial or
             interfere with the interpretation of trial results

          -  Has had major surgery within 3 months before first study drug administration

          -  Has an active infection requiring systemic treatment

          -  Is participating in another therapeutic clinical trial